Clinical Trial Update: Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating nivolumab in prostate cancer with DNA repair defects (ImmunoProst trial) is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Hospital Moinhos de Vento | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN